NANOG gene suppression and replacement of let-7 modulate the stemness, invasion, and apoptosis in breast cancer.


Journal

Gene
ISSN: 1879-0038
Titre abrégé: Gene
Pays: Netherlands
ID NLM: 7706761

Informations de publication

Date de publication:
30 Oct 2021
Historique:
received: 14 03 2021
revised: 06 06 2021
accepted: 13 07 2021
pubmed: 19 7 2021
medline: 17 8 2021
entrez: 18 7 2021
Statut: ppublish

Résumé

In the treatment of breast cancer (BC), as an important type of cancer in women, the specific cells, called cancer stem cells (CSCs), are the reason of failure and metastasis. So, targeting CSCs can be used as a novel strategy in cancer therapy in addition to common therapeutic strategies. According to the importance of CSCs, we tried to find a correlation between stemness and metastatic characteristics of BC cells, to address whether CSCs are a potential target for cancer therapy. Here, we evaluated the NANOG inhibition by siRNA and the increase of Let-7a levels by miRNA mimic in breast cancer cells and the effects of these changes on biologic aspects like cell apoptosis, stemness and invasion. Our results showed that the inhibition of NANOG combined with Let-7a restoration contributed to significant decrease in malignant phenotypes and stemness feature of BC cells. In conclusion, these findings showed that the combination of Let-7a miRNA mimic and Nanog siRNA could be exploited as a new treatment strategy to improve the cancer therapy outcome.

Identifiants

pubmed: 34274471
pii: S0378-1119(21)00439-X
doi: 10.1016/j.gene.2021.145844
pii:
doi:

Substances chimiques

Antigens, CD 0
CDH1 protein, human 0
Cadherins 0
HMGA2 Protein 0
HMGA2 protein, human 0
Lin28A protein, human 0
MicroRNAs 0
NANOG protein, human 0
Nanog Homeobox Protein 0
Octamer Transcription Factor-3 0
POU5F1 protein, human 0
RNA, Small Interfering 0
RNA-Binding Proteins 0
VIM protein, human 0
Vimentin 0
mirnlet7 microRNA, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

145844

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Zeynab Aliyari Serej (ZA)

Department of Applied Cell Sciences, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran; Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.

Ayyub Ebrahimi (A)

Department of Molecular Biology and Genetics, Faculty of Arts and Sciences, Halic University, Istanbul, Turkey.

Tohid Kazemi (T)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.

Souzan Najafi (S)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Mohammad Amini (M)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Parastou Nastarin (P)

Department of Orthodontics, Faculty of Dentistry, Tabriz University of Medical Sciences, Tabriz, Iran.

Elham Baghbani (E)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Behzad Baradaran (B)

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: baradaranb@tbzmed.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH